Associations of demographics, aggravating factors, comorbidities, and treatments with atopic dermatitis severity in China: A national cross-sectional study.
Jiahui Zhao, Zhixin Zhang, Hongguang Chen...
https://pubmed.ncbi.nlm.nih.gov/38431766Actively Recruiting
All Genders
ID05316805
China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project: a National Multicenter Prospective Cohort Study
Led by Peking University First Hospital · Updated on 2024-08-15
100000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a national multicenter prospective cohort study to better understand type 2 inflammatory skin diseases such as dermatitis, eczema, urticaria, pemphigoid, and prurigo nodularis. The study aims to improve diagnosis and treatment by systematically collecting data on current treatment status as well as the effectiveness and safety of various therapies in real clinical settings. This effort is led by the National Clinical Center for Skin and Immune Diseases and sponsored by Peking University First Hospital. This observational study does not involve experimental treatments but gathers information from patients receiving standard care at multiple medical units approved by the National Clinical Center for Skin and Immune Diseases. Data collection includes patient demographics, disease onset age, types of current therapies, and presence of related conditions. The study will follow patients for up to 120 months to observe treatment patterns and disease outcomes over time. Participants will provide information through questionnaires and clinical assessments at baseline and throughout the study period. Measures include the Eczema Area and Severity Index (EASI), Body Surface Area affected, quality of life questionnaires, and disease activity scores related to specific skin conditions. The research team will monitor changes in therapy use, disease severity, and patient quality of life to inform future care improvements. The study started in August 2021 and will continue until December 2031.
CONDITIONS
Brief Title
China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project
Who Can Participate
All Genders
Eligibility Criteria
You may qualify if you...
- Patients must be from medical units approved by the National Clinical Center for Skin and Immune Diseases
- Patients diagnosed with type 2 inflammatory skin diseases including dermatitis/eczema, urticaria, pemphigoid, or prurigo nodularis
You will not qualify if you...
- Patients who do not provide informed consent
- Patients unable to complete questionnaires independently or with investigator guidance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Long-term Monitoring
Duration - Up to 120 months
Participants with type 2 inflammatory skin diseases are observed and assessed over time through questionnaires and clinical evaluations.
Regular visits for assessments from baseline to Month 120
Trial Site Locations
Total: 1 location
1
Peking University First Hospital
Beijing, China
Actively Recruiting
Loading map...
Research Team
Y
Yang Wang, Doctor
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here